Legal & General Group Plc raised its holdings in shares of Regenxbio Inc (NASDAQ:RGNX) by 919.6% during the second quarter, Holdings Channel reports. The fund owned 53,386 shares of the biotechnology company’s stock after buying an additional 48,150 shares during the period. Legal & General Group Plc’s holdings in Regenxbio were worth $3,831,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. BlackRock Inc. grew its position in Regenxbio by 89.9% during the second quarter. BlackRock Inc. now owns 4,218,413 shares of the biotechnology company’s stock valued at $302,671,000 after acquiring an additional 1,997,447 shares during the last quarter. Redmile Group LLC grew its position in Regenxbio by 49.5% during the first quarter. Redmile Group LLC now owns 2,130,972 shares of the biotechnology company’s stock valued at $63,610,000 after acquiring an additional 705,700 shares during the last quarter. Bank of New York Mellon Corp grew its position in Regenxbio by 140.6% during the second quarter. Bank of New York Mellon Corp now owns 319,330 shares of the biotechnology company’s stock valued at $22,911,000 after acquiring an additional 186,595 shares during the last quarter. Botty Investors LLC grew its position in Regenxbio by 8.5% during the first quarter. Botty Investors LLC now owns 202,424 shares of the biotechnology company’s stock valued at $6,042,000 after acquiring an additional 15,886 shares during the last quarter. Finally, WS Management Lllp bought a new position in Regenxbio during the first quarter valued at approximately $5,970,000. Institutional investors and hedge funds own 80.81% of the company’s stock.

A number of brokerages have commented on RGNX. Raymond James reiterated a “buy” rating and set a $76.00 price target on shares of Regenxbio in a research report on Monday, June 25th. BidaskClub cut shares of Regenxbio from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 25th. ValuEngine upgraded shares of Regenxbio from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 10th. TheStreet cut shares of Regenxbio from a “c” rating to a “d+” rating in a research report on Friday, August 10th. Finally, Morgan Stanley increased their price target on shares of Regenxbio from $37.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday, July 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Regenxbio currently has an average rating of “Buy” and an average price target of $77.64.

In other news, CFO Vittal Vasista sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $65.43, for a total value of $490,725.00. Following the transaction, the chief financial officer now owns 123,584 shares in the company, valued at $8,086,101.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kenneth T. Mills sold 7,510 shares of the firm’s stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $66.46, for a total transaction of $499,114.60. Following the completion of the transaction, the insider now owns 348,530 shares in the company, valued at approximately $23,163,303.80. The disclosure for this sale can be found here. Insiders sold 42,520 shares of company stock worth $3,010,214 in the last 90 days. Company insiders own 16.90% of the company’s stock.

Shares of Regenxbio stock opened at $71.75 on Tuesday. Regenxbio Inc has a 52-week low of $23.25 and a 52-week high of $85.10. The company has a market capitalization of $2.24 billion, a PE ratio of -29.22, a PEG ratio of 13.91 and a beta of -1.18.

Regenxbio (NASDAQ:RGNX) last issued its earnings results on Wednesday, August 8th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.23 by ($0.93). Regenxbio had a return on equity of 28.70% and a net margin of 44.44%. The firm had revenue of $40.03 million during the quarter, compared to the consensus estimate of $100.00 million. research analysts forecast that Regenxbio Inc will post 1.64 EPS for the current fiscal year.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Recommended Story: How is the S&P 500 index different from the DJIA?

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regenxbio Inc (NASDAQ:RGNX).

Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.